Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone

Lignende værker

• Venetoclax in Immunoglobulin Light Chain Amyloidosis: Is This the Beginning or the End?
  af: Premkumar, Vikram, et al.
  Udgivet: (2019)
• Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
  af: Mikhael, Joseph R., et al.
  Udgivet: (2012)
• Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone
  af: Kastritis, Efstathios, et al.
  Udgivet: (2019)
• Stem Cell Transplantation Compared With Melphalan Plus Dexamethasone in the Treatment of Immunoglobulin Light Chain Amyloidosis
  af: Gertz, Morie A., et al.
  Udgivet: (2016)
• Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib
  af: Kastritis, E, et al.
  Udgivet: (2017)